Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood pressure cuff

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Blood pressure cuff. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-007711-32 Sponsor Protocol Number: 502.550 Start Date*: 2009-07-15
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ...
    Medical condition: Severe Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-003636-88 Sponsor Protocol Number: KBP5074-3-001 Start Date*: 2022-07-12
    Sponsor Name:KBP BioSciences PTE. Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hype...
    Medical condition: Uncontrolled hypertension in patients who have Stage 3b/4 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066860 Uncontrolled hypertension LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended) LT (Completed) PL (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000039-73 Sponsor Protocol Number: CSPP100A2327 Start Date*: 2005-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administer...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004255-18 Sponsor Protocol Number: CSPP100A2324 Start Date*: 2005-03-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients ≥ 65 years of age with essential hyperten...
    Medical condition: Hypertension
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002469-11 Sponsor Protocol Number: CSPP100A2403 Start Date*: 2008-05-13
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Estudio aleatorizado, doble ciego, de grupos paralelos, multicéntrico, para comparar la eficacia y seguridad de aliskiren 300 mg administrado una vez al día y de aliskiren 150 mg administrado dos v...
    Medical condition: Hipertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000873-40 Sponsor Protocol Number: 1235.20 Start Date*: 2009-01-27
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como tera...
    Medical condition: Hipertensión grave Severe Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001579-35 Sponsor Protocol Number: KBP5074-2-001 Start Date*: 2019-08-07
    Sponsor Name:KBP BioSciences Co., Ltd.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disea...
    Medical condition: Moderate to Severe Chronic Kidney Disease and uncontrolled hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000874-19 Sponsor Protocol Number: 1235.21 Start Date*: 2008-11-19
    Sponsor Name:Boehringer Ingelheim Pharmaceuticals. Inc.
    Full Title: A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg...
    Medical condition: type 2 diabetes and mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002524-27 Sponsor Protocol Number: 14-285 Start Date*: 2014-12-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study blood pressure lowering effects of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women
    Medical condition: Post Partum Hypertension after preeclamptic pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015982-29 Sponsor Protocol Number: UMCU-Vasc-14A Start Date*: 2010-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyper...
    Medical condition: Hypertension in subjects with abdominal obesity and the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059179 Abdominal obesity LLT
    12.1 10052066 Metabolic syndrome LLT
    12.1 10020772 Hypertension LLT
    12.1 10065941 Central obesity LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003618-17 Sponsor Protocol Number: ALT-711-0424 Start Date*: 2008-05-07
    Sponsor Name:JDRF Danielle Alberti Memorial Centre For Diabetes Complications Baker Heart Research Institute
    Full Title: A Randomozed, Placebo-Controlled Trial of Alagebrium in Patients with Insulin-Dependent Type 1 Diabetes and Microalbuminuria
    Medical condition: This is a double-blind phase 2 clinical study to evaluate the effects of alagebrium chloride (ALT-711) versus placebo on albumin excretion rate (as an early marker of diabetic nephropathy) in subje...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003233-14 Sponsor Protocol Number: 18CH129 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Saint Etienne
    Full Title: Evaluation of the neonatal autonomic stress during intubations under Propofol in a population of premature infants under 33 w’GA
    Medical condition: population of premature infants under 33 w’GA requiring intubation for the administration of exogenous surfactant
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10003969 Baby premature LLT
    20.0 100000004855 10020477 Hyaline membrane disease LLT
    20.1 100000004852 10002321 Anesthesia LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003286-17 Sponsor Protocol Number: CCOX189A2428 Start Date*: 2006-01-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in an imp...
    Medical condition: Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    8.0 10031161 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed) GB (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-002157-79 Sponsor Protocol Number: DPB107246 Start Date*: 2006-10-11
    Sponsor Name:GlaxoSmithKline
    Full Title: “A Multi-Center, Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus”
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001899-11 Sponsor Protocol Number: C1701-202 Start Date*: 2019-11-07
    Sponsor Name:Cyclerion Therapeutics, Inc.
    Full Title: A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease
    Medical condition: Stable Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005535-40 Sponsor Protocol Number: 3599-001 Start Date*: 2016-07-21
    Sponsor Name:Baxter Healthcare Corporation
    Full Title: A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 s-apr) Compared to DuraSeal Dural Sealant as an Adjunct ...
    Medical condition: Intra-operative CSF leak
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10024091 Leakage of cerebrospinal fluid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001465-20 Sponsor Protocol Number: FMLD-ARSIDOS-48 Start Date*: 2022-02-11
    Sponsor Name:Laboratorios Farmalíder S.A.
    Full Title: A double-blind, multicenter, randomized clinical trial to assess the efficacy and safety of Montelukast in patients with erosive / inflammatory arthrosis of the hands
    Medical condition: Erosive / inflammatory arthrosis of the hands
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003416 Arthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2017-001156-55 Sponsor Protocol Number: C1171002 Start Date*: 2017-11-24
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-Weeks To...
    Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005397-34 Sponsor Protocol Number: Issue1 Start Date*: 2012-02-24
    Sponsor Name:University Hospital Bristol NHS Foundation Trust
    Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study)
    Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10050081 Neonatal hypoxia PT
    14.1 10036585 - Pregnancy, puerperium and perinatal conditions 10028946 Neonatal hypoxia and asphyxia HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 19:55:34 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA